<DOC>
	<DOCNO>NCT02112110</DOCNO>
	<brief_summary>The purpose study determine absolute bioavailability 150 mg oral dose BMS-791325 relative 100 µg IV infusion [ 13C ] -BMS-791325 .</brief_summary>
	<brief_title>Absolute Bioavailability BMS-791325</brief_title>
	<detailed_description>Primary Purpose : Other : Protocol design ass absolute bioavailability 150 mg ( 2x75 mg tablet ) BMS-791325 administer orally</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com 1 . Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination 2 . Men woman age 18 49 year , inclusive 3 . Women childbearing potential ( WOCBP ) must pregnant breastfeed WOCBP men sexually active WOCBP must agree follow protocol mandate instruction method ( ) contraception study 1 . Any significant acute chronic medical illness 2 . Any current recent gastrointestinal disease surgery could impact upon absorption study drug 3 . Inability tolerate oral medication 4 . Inability venipunctured and/or tolerate venous access 5 . Use tobaccocontaining nicotinecontaining product within 6 month 6 . Recent ( within 6 month study drug administration ) drug alcohol abuse define Diagnostic Statistical Manual Mental Disorders ( 4th Edition ) ( DSM IV ) , Diagnostic Criteria Drug Alcohol Abuse 7 . Any follow 12lead electrocardiogram ( ECG ) prior study drug administration screen Day 1 , confirm repeat ) PR ≥ 210 msec ii ) QRS ≥ 120 msec iii ) QT ≥ 500 msec iv ) QTcF ≥ 450 msec v ) Second third degree heart block h ) Positive urine screen drug abuse ) Positive blood screen hepatitis C antibody , hepatitis B surface antigen , r HIV1 , 2 antibody j ) Any follow screening Day 1 laboratory result outside range specify defined laboratory , confirm repeat analysis : ) Serum creatinine &gt; upper limit normal ( ULN ) ii ) Alanine aminotransferase ( ALT ) &gt; ULN iii ) Aspartate aminotransferase ( AST ) &gt; ULN iv ) Total bilirubin &gt; ULN k ) History significant drug allergy ( anaphylaxis hepatotoxicity )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>